Armata Pharmaceuticals, Inc. (ARMP) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Marina del Rey, CA, アメリカ. 現CEOは Deborah L. Birx.
ARMP を有する IPO日 1994-05-20, 60 名の正社員, に上場 American Stock Excha, 時価総額 $471.83M.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
